Zymeworks

Zymeworks presented at the Wells Fargo conference a hybrid strategy centered on Zanidatamab, license revenues and acquisitions, aiming to build sustainable, risk-adjusted cash flows. Zanidatamab received FDA approval for first-line treatment of gastric and gastroesophageal adenocarcinoma; Jazz Pharmaceuticals raises its peak sales forecast to $3–5 billion annually. The company financed buybacks and the Theravance acquisition with non-recourse debt (totaling $600 million) and plans to provide further guidance after the transaction closes. Future value drivers include potential Zanidatamab oncology indications, notably breast cancer, and the monetization of other pipeline assets. » More on de.investing.com

Zymeworks stock climbed to a new 52-week high of $30.75 after a year-to-date gain of 115.42% and a market capitalization of about $2.13 billion. Analysts maintain a largely positive consensus with price targets between $31 and $60; several firms raised targets or ratings. Zymeworks also received FDA approval for therapies with Ziihera for HER2-positive gastric and gastroesophageal adenocarcinoma, and a definitive acquisition agreement for Theravance Biopharma at $17 per share was announced, including a contingent value right for ampreloxetine. » More on de.investing.com

The U.S. approval of the cancer drug Ziihera triggers a contractual one-time payment of $0.25 billion to Zymeworks. H.C. Wainwright raised the price target from $51 to $55 and reaffirmed the buy recommendation. Zymeworks' business model combines in-house research with strategic partners and benefits from oncology growth trends. » More on finanzen.net

Zymeworks shares climbed in premarket trading as the FDA decision on the PDUFA date of August 25, 2026, for zanidatamab (Ziihera) for HER2-positive gastric and gastroesophageal adenocarcinoma is awaited. Approval would immediately trigger a U.S. milestone payment of $250 million and could enable further global payments of up to $190 million. Analysts backed their assessments and raised price targets ahead of the date, and the planned acquisition of Theravance Biopharma is expected to strengthen the portfolio and cash flows with YUPELRI. The share price rise comes despite a weak overall market and a difficult biotech environment; the stock is trading at its highest level in more than a year. » More on de.investing.com

Zymeworks has entered a collaboration with Gandeeva Therapeutics to generate cryo‑electron microscopy structural data to aid discovery of antibody therapeutics. The partnership focuses on high‑resolution visualization of antibody‑antigen interfaces, in particular epitope mapping on small, flexible antigens. Gandeeva has already demonstrated a structure determination at 2.6 Å resolution that is intended to support selection and optimization of antibody lead candidates. In response, Zymeworks shares rose sharply in pre‑market trading. » More on de.investing.com